Table 3.
Antipseudomonal inhaled and i.v. antibiotic regimens among study PEx
| Antibiotic | Two i.v. and Zero Inhaled (n = 5,373 PEx [65%]) | Two i.v. and One Inhaled (n = 1,375 PEx [17%]) | One i.v. and One Inhaled (n = 602 PEx [7%]) | One i.v. and Zero Inhaled (n = 961 PEx [12%]) |
|---|---|---|---|---|
| i.v. aminoglycoside* | 5,134 (96) | 1,230 (89) | 41 (7) | 169 (18) |
| i.v. β-lactam† | 5,270 (98) | 1,360 (99) | 527 (88) | 693 (72) |
| i.v. fluoroquinolone‡ | 546 (10) | 240 (17) | 34 (6) | 99 (10) |
| Inhaled tobramycin | N/A | 1,164 (85) | 528 (88) | N/A |
| Inhaled colistin | N/A | 157 (11) | 71 (12) | N/A |
| Inhaled aztreonam | N/A | 76 (6) | 16 (3) | N/A |
| Inhaled amikacin | N/A | 15 (1) | 5 (1) | N/A |
Definition of abbreviations: i.v. = intravenous; N/A = not applicable; PEx = pulmonary exacerbation.
Data are presented as n (%).
*
i.v. aminoglycosides include amikacin, gentamicin, kanamycin, and tobramycin.
†i.v. β-lactams include piperacillin-tazobactam, ticarcillin-clavulanate, ceftazidime, cefepime, doripenem, imipenem-cilastatin, meropenem, aztreonam, colistin, and polymixin B.
‡i.v. Fluoroquinolones include ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin.